Skye Bioscience Inc.(US:SKYE) Globenewswire·2025-12-29 14:06Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. on behalf of investors who acquired Skye securities during the specified Class Period, alleging misleading information regarding the company's lead candidate, nimacimab [1][2]. Company Overview - Skye Bioscience, Inc. is a clinical-stage biotechnology company based in San Diego, focusing on developing treatments for obesity and metabolic diseases [2]. Legal Proceedings - The lawsuit claims that throughout the Class Period, the defendants misled investors about the prospects of nimacimab [2]. - Investors are given a deadline of January 16, 2026, to seek appointment as lead plaintiff representatives of the class [2]. Stock Performance - On October 6, 2025, Skye published topline findings from its 26-week Phase 2a CBeyond trial of nimacimab, which failed to meet its primary weight-loss endpoint compared to placebo. Following this announcement, Skye's stock price dropped by $2.85 per share, approximately 60%, closing at $1.90 [3].